CA3010982A1 - Alpha chain of the high-affinity ige receptor (fceria) - Google Patents
Alpha chain of the high-affinity ige receptor (fceria) Download PDFInfo
- Publication number
- CA3010982A1 CA3010982A1 CA3010982A CA3010982A CA3010982A1 CA 3010982 A1 CA3010982 A1 CA 3010982A1 CA 3010982 A CA3010982 A CA 3010982A CA 3010982 A CA3010982 A CA 3010982A CA 3010982 A1 CA3010982 A1 CA 3010982A1
- Authority
- CA
- Canada
- Prior art keywords
- fceria
- alpha chain
- ige receptor
- affinity ige
- alanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000009438 IgE Receptors Human genes 0.000 title abstract 2
- 108010073816 IgE Receptors Proteins 0.000 title abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 3
- 235000004279 alanine Nutrition 0.000 abstract 3
- 229960003767 alanine Drugs 0.000 abstract 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 2
- 239000004471 Glycine Substances 0.000 abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 2
- 229940024606 amino acid Drugs 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 229960002449 glycine Drugs 0.000 abstract 2
- 235000004400 serine Nutrition 0.000 abstract 2
- 229960001153 serine Drugs 0.000 abstract 2
- 235000002374 tyrosine Nutrition 0.000 abstract 2
- 229960004441 tyrosine Drugs 0.000 abstract 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- 229960005261 aspartic acid Drugs 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 229960002989 glutamic acid Drugs 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- 235000004554 glutamine Nutrition 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- 229960002743 glutamine Drugs 0.000 abstract 1
- 235000014705 isoleucine Nutrition 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 235000005772 leucine Nutrition 0.000 abstract 1
- 229960003136 leucine Drugs 0.000 abstract 1
- 235000006109 methionine Nutrition 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 229960004452 methionine Drugs 0.000 abstract 1
- 235000008729 phenylalanine Nutrition 0.000 abstract 1
- 229960005190 phenylalanine Drugs 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 235000008521 threonine Nutrition 0.000 abstract 1
- 229960002898 threonine Drugs 0.000 abstract 1
- 229960004799 tryptophan Drugs 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
- 229960004295 valine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020009.3A EP3192806A1 (en) | 2016-01-13 | 2016-01-13 | Alpha chain of the high-affinity ige receptor (fceria) |
| EP16020009.3 | 2016-01-13 | ||
| PCT/EP2017/050646 WO2017121842A1 (en) | 2016-01-13 | 2017-01-13 | Alpha chain of the high-affinity ige receptor (fceria) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3010982A1 true CA3010982A1 (en) | 2017-07-20 |
Family
ID=55357837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3010982A Abandoned CA3010982A1 (en) | 2016-01-13 | 2017-01-13 | Alpha chain of the high-affinity ige receptor (fceria) |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190127438A1 (enExample) |
| EP (2) | EP3192806A1 (enExample) |
| JP (1) | JP2019510737A (enExample) |
| CN (1) | CN108473551A (enExample) |
| AU (1) | AU2017207854A1 (enExample) |
| CA (1) | CA3010982A1 (enExample) |
| RU (1) | RU2018129024A (enExample) |
| WO (1) | WO2017121842A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113316635A (zh) | 2018-10-29 | 2021-08-27 | 科德克希思公司 | 工程化dna聚合酶变体 |
| CN111100210B (zh) * | 2019-01-30 | 2022-04-19 | 武汉九州钰民医药科技有限公司 | 一种Fc融合蛋白及其应用 |
| MX2022000285A (es) * | 2019-07-08 | 2022-02-03 | Gi Innovation Inc | Dimero de polipeptido con alto contenido de acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige y composicion farmaceutica que comprende el mismo. |
| CN110716054A (zh) * | 2019-09-11 | 2020-01-21 | 天津医科大学 | 一种血清亲细胞性免疫球蛋白e的定量检测试剂盒 |
| FR3108515B1 (fr) * | 2020-03-26 | 2022-03-25 | Ct Hospitalier Universitaire Toulouse | Colonne d’aphérèse pour le traitement de la polyarthrite rhumatoïde |
| US20230279124A1 (en) * | 2020-07-17 | 2023-09-07 | Gi Innovation, Inc. | Fusion protein comprising ige fc receptor alpha subunit extracellular domain and anti-il-4r antibody, and use thereof |
| CN120883058A (zh) * | 2023-03-29 | 2025-10-31 | 基立福环球运营有限公司 | 具有降低的FcεRIβ自身抗体水平的血浆制品的组合物及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06104122B2 (ja) | 1985-09-19 | 1994-12-21 | 東レ株式会社 | β▲下２▼−ミクログロブリン除去カラム |
| US5985599A (en) | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
| US4962035A (en) | 1987-12-01 | 1990-10-09 | President And Fellows Of Harvard College | DNA encoding IgE receptor alpha-subunit or fragment thereof |
| CA2190268C (en) | 1994-05-13 | 2000-01-25 | Wolfgang Bohm | Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood |
| IL116436A (en) * | 1995-12-18 | 2006-12-31 | Yissum Res Dev Co | Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND |
| MY120425A (en) | 1996-07-26 | 2005-10-31 | Novartis Ag | Fusion polypeptides |
| GB9715387D0 (en) | 1997-07-23 | 1997-09-24 | Gould Hannah J | Immunoglobulin-binding polypeptides and their use |
| US6057127A (en) * | 1998-01-29 | 2000-05-02 | Heska Corporation | Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| CA2385778A1 (en) * | 1999-09-21 | 2001-03-29 | Isis Innovation Limited | Modulation of ige receptor cell surface expression |
| WO2002006298A1 (en) * | 2000-07-13 | 2002-01-24 | Hyseq, Inc. | Soluble immunoglobulin e receptor alpha like molecules |
| US8354109B2 (en) | 2005-12-13 | 2013-01-15 | Suppremol Gmbh | Multimeric Fc receptor polypeptides |
| WO2012140214A1 (en) | 2011-04-13 | 2012-10-18 | Biomay Ag | IMMUNOAFFINITY SEPARATION MATERIALS COMPRISING ANTI-IgE ANTIBODY DERIVATIVES |
| CN102660569B (zh) | 2012-04-21 | 2013-11-06 | 大连理工大学 | 一种重组人IgE受体蛋白的制备方法及应用 |
-
2016
- 2016-01-13 EP EP16020009.3A patent/EP3192806A1/en not_active Ceased
-
2017
- 2017-01-13 RU RU2018129024A patent/RU2018129024A/ru not_active Application Discontinuation
- 2017-01-13 AU AU2017207854A patent/AU2017207854A1/en not_active Abandoned
- 2017-01-13 JP JP2018536507A patent/JP2019510737A/ja not_active Withdrawn
- 2017-01-13 CN CN201780005678.0A patent/CN108473551A/zh active Pending
- 2017-01-13 WO PCT/EP2017/050646 patent/WO2017121842A1/en not_active Ceased
- 2017-01-13 US US16/068,406 patent/US20190127438A1/en not_active Abandoned
- 2017-01-13 CA CA3010982A patent/CA3010982A1/en not_active Abandoned
- 2017-01-13 EP EP17700360.5A patent/EP3402813A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3192806A1 (en) | 2017-07-19 |
| JP2019510737A (ja) | 2019-04-18 |
| CN108473551A (zh) | 2018-08-31 |
| EP3402813A1 (en) | 2018-11-21 |
| RU2018129024A3 (enExample) | 2020-05-29 |
| US20190127438A1 (en) | 2019-05-02 |
| AU2017207854A1 (en) | 2018-06-07 |
| WO2017121842A1 (en) | 2017-07-20 |
| RU2018129024A (ru) | 2020-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3010982A1 (en) | Alpha chain of the high-affinity ige receptor (fceria) | |
| EA202090090A1 (ru) | Включение неприродных нуклеотидов и способы с ними | |
| EP4442816A3 (en) | Mutated glycoprotein of vesicular stomatitis virus | |
| CY1124019T1 (el) | Σταθεροποιημενη διαλυτη πρωτεϊνη προσυντηξης rsv f για χρηση στην προφυλαξη απο λοιμωξη rsv | |
| RU2016140627A (ru) | Бета-лактамазы с улучшенными свойствами для лечения | |
| EA201792651A1 (ru) | Аденовирусные полинуклеотиды и полипептиды | |
| MX2017004488A (es) | Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso. | |
| EP3936141A3 (en) | Anti-senescence compounds and uses thereof | |
| MX2018000697A (es) | Peptidos anti-inflamatorios y usos de los mismos. | |
| NZ579566A (en) | Modified fgf-21 polypeptides and their uses | |
| MX2017006748A (es) | Composiciones de aminoácidos para el tratamiento de síntomas de enfermedades. | |
| EP4374913A3 (en) | Novel human serum albumin mutant | |
| MX2022007881A (es) | Proteina f mutante del virus sincitial respiratorio (rsv) y usos de la misma. | |
| GEP20207139B (en) | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine | |
| BR112019003816A2 (pt) | composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição | |
| NZ736642A (en) | Short synthetic peptide for treatment and/or prophylaxis of autoimmune and inflammatory disorders | |
| CR20180008A (es) | Variantes de il-37 | |
| CL2020000862A1 (es) | Composición de proteína de guisante con calidad nutricional mejorada. | |
| RU2017125261A (ru) | Способ и промежуточные соединения для получения прегабалина | |
| WO2016094829A8 (en) | Self-assembling peptides comprising non-ionic polar amino acids | |
| IN2015DN03883A (enExample) | ||
| ATE418877T1 (de) | Essbare bzw. trinkbare sowie medizinisch verwendbare, die körpertemperatur erhöhende aminosäurezusammensetzung | |
| WO2015041924A3 (en) | Recombinant respiratory syncytial virus (rsv) and caccines | |
| HK1243329A1 (zh) | 谷氨酸草酰乙酸转氨酶1(got1)、其制剂、产生方法及用途 | |
| WO2018130212A3 (zh) | 胃蛋白抗性改良和催化效率提高的植酸酶YkAPPA突变体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220713 |
|
| FZDE | Discontinued |
Effective date: 20220713 |